September 21, 2017 9:13 PM ET

Pharmaceuticals

Company Overview of Shandong Buchang Pharmaceuticals Co., Ltd.

Company Overview

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicines in China. It offers its products for cardiac and cerebral vascular, diabetes, urinary and digestive, respiratory, gynecological, and other diseases. The company was founded in 1993 and is based in Xi'an, China. Shandong Buchang Pharmaceuticals Co., Ltd. is a subsidiary of Shanghai Zhangjiang (Group) co., LTD.

Nanyang International Building

No. 50 Gaoxin Road

Xi'an,  712000

China

Founded in 1993

7,491 Employees

Phone:

86 29 8831 8318

Key Executives for Shandong Buchang Pharmaceuticals Co., Ltd.

Shandong Buchang Pharmaceuticals Co., Ltd. does not have any Key Executives recorded.

Shandong Buchang Pharmaceuticals Co., Ltd. Key Developments

Shandong Buchang Pharmaceuticals Co., Ltd., Board Meeting, Sep 15, 2017

Shandong Buchang Pharmaceuticals Co., Ltd., Board Meeting, Sep 15, 2017. Agenda: To discuss and approve the proposal of adding some idle raised funds used for temporarily supplementing current capital.

Shandong Buchang Pharma Enters into Agreement with Nantong Lianya Pharma

Shandong Buchang Pharmaceutical Co Ltd. has entered into agreement with Nantong Lianya Pharmaceutical Co., Ltd. for development, supplement and sale of five drug products. Shandong Buchang signed the development, supply and sale agreements for five kinds of products such as nifedipine controlled release tablets to determine the cooperation products hair, supply and sales and other related matters, including the agreement involved in R&D investment by the company to undertake 55% of the total research and development fees. The transaction enables Shandong Buchang and Nantong to expand its business, enrich the product line and to strengthen its market competitiveness. The transaction enables Shandong Buchang and Nantong to expand its business, enrich the product line and to strengthen its market competitiveness.

Shandong Buchang Pharmaceuticals Co., Ltd. Announces Earnings Results for the First Half of 2017

Shandong Buchang Pharmaceuticals Co., Ltd. announced earnings results for the first half of 2017. For the first half, the company announced basic earnings per share of CNY 0.9945 and weighted average return on net assets of 5.31%.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 3, 2017
Qionglai Tianyin Pharmaceutical Co., Ltd.
Merger/Acquisition
June 23, 2017
Jiuzhoutong Pharmaceutical Group Hubei Pharmaceutical Co., Ltd.
Private Placement
June 21, 2017
Wuhan Ruifu Medical Health Equity Investment Partnership (Limited Partnership)
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shandong Buchang Pharmaceuticals Co., Ltd., please visit www.buchang.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.